Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $4.0B | $4.0B | $4.0B | $4.1B | $4.0B | $3.5B | $2.9B | $2.6B | $2.3B | $1.9B | $1.7B | $1.4B | $1.3B | $1.2B | $1.1B | $1.1B | $1.1B | $1.2B | $1.3B | $1.2B | $1.1B |
| Bruttoergebnis | $1.3B | $1.2B | $1.3B | $1.5B | $1.5B | $1.3B | $1.1B | $958M | $840M | $701M | $644M | $531M | $473M | $395M | $392M | $402M | $385M | $423M | $511M | $478M | $407M |
| Bruttomarge % | 32.2% | 30.5% | 32.9% | 36.4% | 36.8% | 37.7% | 36.7% | 36.6% | 37.1% | 37.7% | 38.3% | 39.0% | 36.4% | 33.9% | 34.7% | 35.2% | 34.0% | 35.2% | 38.0% | 38.9% | 38.4% |
| Betriebsergebnis (EBIT) | $494M | $508M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M | $206M | $178M | $151M | $166M | $174M | ($299M) | $170M | ($450M) | $227M | $188M |
| Operative Marge % | 12.3% | 12.7% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% | 15.1% | 13.7% | 13.0% | 14.7% | 15.2% | -26.3% | 14.1% | -33.5% | 18.5% | 17.8% |
| Jahresüberschuss | ($240M) | ($144M) | $10M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | $103M | $97M | $110M | ($337M) | $114M | ($522M) | $154M | ($56M) |
| Nettomarge % | -6.0% | -3.6% | 0.2% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% | 10.9% | 9.8% | 8.8% | 8.6% | 9.6% | -29.7% | 9.5% | -38.8% | 12.6% | -5.3% |
| EBITDA | — | $411M | $581M | $1.0B | $986M | $820M | $768M | $563M | $507M | $458M | $377M | $305M | $286M | $256M | $244M | $260M | ($205M) | $263M | ($356M) | $322M | $273M |
| Ergebnis je Aktie (EPS) | $-4.85 | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 | $2.12 | $2.01 | $2.14 | $-5.38 | $1.74 | $-7.76 | $2.25 | $-0.80 |
| Ausstehende Aktien (Mio.) | — | 50M | 52M | 51M | 51M | 51M | 51M | 50M | 49M | 49M | 48M | 48M | 48M | 48M | 48M | 51M | 63M | 66M | 67M | 69M | 70M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für CRL. /companies/us/CRL
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms